Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LRRK2 | Q5S007 | 8/20 | 0.59 |
| ▸ | STK4 | Q13043 | 12/20 | 0.53 |
| ▸ | STK3 | Q13188 | 12/20 | 0.53 |
| ▸ | NUDT1 | P36639 | 3/20 | 0.51 |
| ▸ | TAAR1 | Q96RJ0 | 1/20 | 0.50 |
| ▸ | FYN | P06241 | 1/20 | 0.49 |
| ▸ | IGF1R | P08069 | 1/20 | 0.48 |
| ▸ | SGK1 | O00141 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31734890 | 1.00 | LRRK2 (0.59) | LRRK2STK4STK3NUDT1TAAR1 | |
| SCHEMBL26953278 | 0.87 | SGK1 (0.57) | LRRK2STK4STK3TAAR1FYN | |
| SCHEMBL31735012 | 0.87 | SGK1 (0.57) | LRRK2STK4STK3TAAR1FYN | |
| SCHEMBL26953245 | 0.86 | CDK2 (0.53) | LRRK2STK4STK3TAAR1FYN | |
| SCHEMBL31735005 | 0.86 | LRRK2 (0.59) | LRRK2STK4STK3SGK1 | |
| SCHEMBL26953170 | 0.86 | LRRK2 (0.59) | LRRK2STK4STK3SGK1 | |
| SCHEMBL31734958 | 0.86 | CDK2 (0.53) | LRRK2STK4STK3TAAR1FYN | |
| SCHEMBL31734861 | 0.83 | CYP2A6 (0.55) | LRRK2STK3NUDT1SGK1 | |
| SCHEMBL26953243 | 0.83 | CYP2A6 (0.55) | LRRK2STK3NUDT1SGK1 | |
| SCHEMBL31735072 | 0.83 | SGK1 (0.46) | LRRK2FYNIGF1RSGK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2023239727-A1 | LATS INHIBITORS AND USES THEREOF | THE USA, AS REPRESENTED BY THE SECRETARY, DEPT. OF HEALTH AND HUMAN SERVICES (US) | 2023-12-14 | — | — | WO | disclosed |